Vertex Pharmaceuticals

Biotechnology

VRTX

$ 427 (0.92)%

Share price

$ 110 bn

Market Cap

$ 101 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0x the weighted average for S&P 500

FY2020

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Vertex Pharmaceuticals reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 13 Kt (-0.38 /-2.7% y-o-y).

No public disclosure of Scope 3 emissions has been found for Vertex Pharmaceuticals at the moment.

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2020Q4	13	5.6	7.8
2019Q4	14	5.8	8
2018Q4	17	5.7	11
2017Q4	17	6	11

Vertex Pharmaceuticals

Carbon footprint

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Vertex Pharmaceuticals's carbon footprint

Company environmental metrics